PURPOSE: Defining the site of recurrent disease early after definitive treatment for a localized prostate cancer is a critical issue as it may greatly influence the subsequent therapeutic strategy or patient management. METHODS: A systematic review of the literature was performed by searching Medline from January 1995 up to January 2011. Electronic searches were limited to the English language, and the keywords prostate cancer, radiotherapy [RT], high intensity focused ultrasound [HIFU], cryotherapy [CRIO], transrectal ultrasound [TRUS], magnetic resonance [MRI], PET/TC, and prostate biopsy were used. RESULTS: Despite the fact that diagnosis of a local recurrence is based on PSA values and kinetics, imaging by means of different techniques may be a prerequisite for effective disease management. Unfortunately, prostate cancer local recurrences are very difficult to detect by TRUS and conventional imaging that have shown limited accuracy at least at early stages. On the contrary, functional and molecular imaging such as dynamic contrast-enhanced MRI (DCE-MRI), and diffusion-weighted imaging (DWI), offers the possibility of imaging molecular or cellular processes of individual tumors. Recently, PET/CT, using 11C-choline, 18F-fluorocholine or 11C-acetate has been successfully proposed in detecting local recurrences as well as distant metastases. Nevertheless, in controversial cases, it is necessary to perform a biopsy of the prostatic fossa or a biopsy of the prostate to assess the presence of a local recurrence under guidance of MRI or TRUS findings. CONCLUSION: It is likely that imaging will be extensively used in the future to detect and localize prostate cancer local recurrences before salvage treatment.
PURPOSE: Defining the site of recurrent disease early after definitive treatment for a localized prostate cancer is a critical issue as it may greatly influence the subsequent therapeutic strategy or patient management. METHODS: A systematic review of the literature was performed by searching Medline from January 1995 up to January 2011. Electronic searches were limited to the English language, and the keywords prostate cancer, radiotherapy [RT], high intensity focused ultrasound [HIFU], cryotherapy [CRIO], transrectal ultrasound [TRUS], magnetic resonance [MRI], PET/TC, and prostate biopsy were used. RESULTS: Despite the fact that diagnosis of a local recurrence is based on PSA values and kinetics, imaging by means of different techniques may be a prerequisite for effective disease management. Unfortunately, prostate cancer local recurrences are very difficult to detect by TRUS and conventional imaging that have shown limited accuracy at least at early stages. On the contrary, functional and molecular imaging such as dynamic contrast-enhanced MRI (DCE-MRI), and diffusion-weighted imaging (DWI), offers the possibility of imaging molecular or cellular processes of individual tumors. Recently, PET/CT, using 11C-choline, 18F-fluorocholine or 11C-acetate has been successfully proposed in detecting local recurrences as well as distant metastases. Nevertheless, in controversial cases, it is necessary to perform a biopsy of the prostatic fossa or a biopsy of the prostate to assess the presence of a local recurrence under guidance of MRI or TRUS findings. CONCLUSION: It is likely that imaging will be extensively used in the future to detect and localize prostate cancer local recurrences before salvage treatment.
Authors: Vincenzo Scattoni; Marco Roscigno; Marco Raber; Francesco Montorsi; Roberto Bertini; Lina Bua; Luigi Da Pozzo; Patrizio Rigatti Journal: Arch Ital Urol Androl Date: 2002-09
Authors: Martin Heinisch; Albert Dirisamer; Wolfgang Loidl; Franz Stoiber; Bernhard Gruy; Silke Haim; Werner Langsteger Journal: Mol Imaging Biol Date: 2006 Jan-Feb Impact factor: 3.488
Authors: Ludwig Rinnab; Felix M Mottaghy; Norbert M Blumstein; Sven N Reske; Richard E Hautmann; Kathrin Hohl; Peter Möller; Thomas Wiegel; Rainer Kuefer; Juergen E Gschwend Journal: BJU Int Date: 2007-10 Impact factor: 5.588
Authors: A W Partin; J D Pearson; P K Landis; H B Carter; C R Pound; J Q Clemens; J I Epstein; P C Walsh Journal: Urology Date: 1994-05 Impact factor: 2.649
Authors: J Amanie; H S Jans; M Wuest; N Pervez; A Murtha; N Usmani; D Yee; R Pearcey; B Danielson; S Patel; R Macewan; C Field; D Robinson; J Wilson; D Lewis; M Parliament; A J B McEwan Journal: Curr Oncol Date: 2013-04 Impact factor: 3.677
Authors: Baowei Fei; Olayinka A Abiodun-Ojo; Akinyemi A Akintayo; Oladunni Akin-Akintayo; Funmilayo Tade; Peter T Nieh; Viraj A Master; Mehrdad Alemozaffar; Adeboye O Osunkoya; Mark M Goodman; David M Schuster Journal: J Urol Date: 2019-07-08 Impact factor: 7.450
Authors: Alex Z Fu; Huei-Ting Tsai; Reina Haque; Marianne Ulcickas Yood; Stephen K Van Den Eeden; Andrea E Cassidy-Bushrow; Yingjun Zhou; Nancy L Keating; Matthew R Smith; David S Aaronson; Arnold L Potosky Journal: World J Urol Date: 2016-04-15 Impact factor: 4.226
Authors: L Van den Bergh; S Isebaert; M Koole; R Oyen; S Joniau; E Lerut; C M Deroose; F De Keyzer; H Van Poppel; K Haustermans Journal: Strahlenther Onkol Date: 2013-09 Impact factor: 3.621
Authors: Francesca V Mertan; Matthew D Greer; Sam Borofsky; Ismail M Kabakus; Maria J Merino; Bradford J Wood; Peter A Pinto; Peter L Choyke; Baris Turkbey Journal: Top Magn Reson Imaging Date: 2016-06